drugset

drugset / Trial / NCT05033145

Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

NCT05033145 ↗

Phase 3 Completed 312 enrolled HRH Pharmaceuticals Limited Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute · collab GALZU INSTITUTE OF RESEARCH, TEACHING, SCIENCE AND APPLIED TECHNOLOGY, Brazil · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase III, single-center with co-participating units, randomized, double-blind, parallel, placebo-controlled clinical study

Timeline

Start: 2022-01-15
Primary completion: 2022-07-27
Completion: 2022-07-27

Publications

da Silva RM, Gebe Abreu Cabral P, de Souza SB, Arruda RF, Cabral SPF, de Assis ALEM, Martins YPM, Tavares CAA, Viana Junior AB, Chang J, Lei P. Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19. Front Med (Lausanne). 2023 Mar 14;10:1143485. doi: 10.3389/fmed.2023.1143485. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azvudine	Small molecule	5 mg	—

Indications